Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update (2023)

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update

22/03/2023 8:05pm

GlobeNewswire Inc.

Atossa Therapeutics (NASDAQ:ATOS)
Intraday Stock Chart

Friday 24 March 2023

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in cancer, today announced financial results for the fiscal quarter and fiscal year ended December 31, 2022 and provided an update on recent company developments.

Key developments from Q4 2022 and year to date include:

(Video) "The Important Role For Inhalation Therapy In Oncology" Atossa Therapeutics (ATOS) Tribe 8-25-2022

Initiation and First Patient Dosed in Phase 2 EVANGELINE Study – EVANGELINE (Endoxifen Versus exemestANe GosEreLIn), is our Phase 2 randomized non-inferiority study of (Z)-endoxifen compared to exemestane plus goserelin as a neoadjuvant treatment for premenopausal women with Grade 1 or 2 ER+ / HER2- breast cancer. Participants receive neoadjuvant treatment for up to six months, followed by surgery. Several FDA-approved neoadjuvant therapies exist for ER- breast cancers, but few exist for ER+ patients, which account for approximately 78% of breast cancers. We expect to enroll approximately 175 patients at up to 25 sites across the United States.

Continued Enrollment in Phase 2 Karisma-Endoxifen Study – The Karisma-Endoxifen study is our randomized, double-blind, placebo-controlled trial of healthy, pre-menopausal women with increased breast density. The treatment cohort receives daily doses of (Z)-endoxifen for six months, over the course of which mammograms will be conducted to measure reduction in mammographic breast density (MBD). Patients will also be given a mammogram at 24 months to assess the durability of the MBD changes. MBD affects more than 10 million women in the United States and many millions more worldwide. Increased MBD reduces the ability of mammograms to detect cancer. Studies have also shown that women with MBD have an increased risk of developing breast cancer and that the higher the MBD, the higher the incidence of breast cancer. We expect to fully enroll the study by the end of 2023.

Initiation of New Study Arm in the Ongoing Phase 2 I-SPY 2 Clinical Trial – (Z)-endoxifen is being evaluated in a new study arm of the ongoing I-SPY 2 clinical trial. The I-SPY 2 trial evaluates neoadjuvant treatments for locally advanced breast cancer and is a collaborative effort among academic investigators from major cancer research centers across the United States, Quantum Leap Healthcare Collaborative, the U.S. Food and Drug Administration, and the Foundation for the National Institutes of Health (FNIH) Cancer Biomarkers Consortium. Approximately 20 patients will be treated with (Z)-endoxifen for up to 24 weeks prior to surgery.

Additional Intellectual Property Protection for (Z)-endoxifen – The United States Patent and Trademark Office granted a new patent (No. 11,572,334) directed to (Z)-endoxifen encapsulated in an enteric capsule. Enteric capsules have an acid resistant coating to prevent them from dissolving when they pass through the stomach. Enteric capsules are dissolved when they pass through an alkaline environment, which is usually when they reach the small intestine. Delivering oral (Z)-endoxifen via an enteric capsule prevents breakdown of the endoxifen in the stomach. This patent further reinforces Atossa’s broad Intellectual Property portfolio related to (Z)-endoxifen.

Investment in Dynamic Cell Therapies, Inc. (DCT) – DCT is a privately held, venture capital backed developer of CAR-T therapies in the pre-clinical phase of developing controllable CAR-T cells to address difficult-to-treat cancers. Its platform technology of dynamic control of engineered T-cells is designed to improve the safety, efficacy, and durability of CAR-T cell therapies. Our investment totaled $4.7 million and resulted in Atossa owning approximately 19% of the outstanding capital stock of DCT.

(Video) ATOS Stock: Can Atossa Therapeutics Potentially Triple While Remaining Safe At The Same Time?

“Our focus remains on both helping reduce the incidence of breast cancer and changing the treatment paradigm for patients who are not benefiting from, or are unable to tolerate, currently approved therapies,” said Dr. Steven Quay, Atossa’s President and Chief Executive Officer. “With a strong balance sheet and three Phase 2 trials underway, we are well positioned to continue accelerating the development of (Z)-endoxifen, which we feel has the potential to address significant unmet needs across the continuum of breast cancer.”


As of December 31, 2022, we had cash, cash equivalents and restricted cash of $111,000.

Results of Operations

Comparison of Years Ended December 31, 2022and 2021

(Video) Atossa Therapeutics Stock, Good News ATOS | Atossa Therapeutics Share Price Prediction & Analysis

Revenue and Cost of Revenue:

For the years ended December 31, 2022and 2021, we have no source of sustainable revenue and no associated cost of revenue.

Operating Expenses:

The following table provides a breakdown of major categories within Research and Development (R&D) and General and Administrative (G&A) expenses for the years ended December 31, 2022 and2021, together with the dollar change in those categories:

Research and Development
Clinical trials$10,225$4,656$5,569
Stock-based compensation2,3931,591802
Professional fees1,242454788
Exclusivity agreements(700)1,000(1,700)
Research and Development Total$15,083$9,210$5,873
General and Administrative
Stock-based compensation4,3953,676719
Professional fees1,6252,317(692)
General and Administrative Total$12,608$11,311$1,297

Total operating expenses were $27,691for the year ended December 31, 2022, which wasan increase of $7,170, or 35%from the year ended December 31, 2021. Operating expenses for 2022consisted of R&Dexpenses of $15,083and G&Aexpenses of $12,608. Operating expenses for 2021consisted of R&D expenses of $9,210and G&A expenses of $11,311. Factors contributing tothe increasedoperating expenses in the year ended December 31, 2022 areexplained below.

(Video) Why is Atossa Therapeutics Stock UP 96% in just 4 days | $ATOS BiotTech Skyrocketing | Penny Stocks

R&DExpenses: R&D expenses for the year ended December 31, 2022, were $15,083, an increase of $5,873or 64% from total R&D expenses for the year ended December 31,2021of $9,210. Key changes were as follows:

  • The increase in R&D expense was attributed primarilyto increased spending on clinical and non-clinical trials of $5,569 compared to the prior year perioddue to additional pre-clinical toxicology studies inour (Z)-endoxifen and AT-H201 programs as well as increasedtrial costs and manufacturing expenses for (Z)-endoxifen.
  • R&D compensation increased$393 in 2022 compared to the prior year period due to increased headcount, salary, bonuses andbenefits during 2022.
  • Stock-based compensation, which is a non-cash charge,increased$802 due to the increased number of options being expensedas well as theweighted average fairvalue of options amortizing in 2022 was higher compared to the prior year period.
  • Professional fees increased $788 compared to the prior year period,due primarily to a CAR-T technology market analysis performed during 2022.
  • In 2022, the Companyreceiveda refund of$1,000 from the research institutionwith whichthe Company had an exclusive right tonegotiate for the acquisition of the worldwide rights to two oncology R&D programs.In 2021, R&D expenses included $1,000attributable to the same one-time exclusivity fee.Finally, in 2022, wepaid $300for the exclusive right to negotiate with anotherCAR-T Company. Net,theexclusivity agreements caused a decrease in expenses of $1,700 compared to the prior year period.

    G&A Expenses: G&A expenses were $12,608for the year ended December 31, 2022, an increase of $1,297, or 11%from total G&A expenses for the year ended December 31, 2021of $11,311.Key changes were as follows:

  • The increase in G&A expense for the year ended December 31, 2022 compared to the prior year period, wasinpartattributable to the increase in compensation expense of$663 in 2022 due to an increase in headcount,hourly wages, salariesandbonus accruals.
  • Non-cash stock-based compensationexpense also increased by $719due to the increased number of options being expensedas well as theweighted average fairvalue of options amortizing in 2022 was higher compared to the prior year period.
  • Professional feesdecreased by $692 in 2022 compared to the prior year period, due primarily to a decrease inproxy costs for investor outreach.
  • Legal feesincreased $601 in 2022 compared to the prior year period, due to higher patent activity in 2022 for (Z)-endoxifen and our immunotherapy research.

    Interest Income:Interest incomewas $877for the year ended December 31, 2022 compared to the prior year period of $6. The increase isdue to theinvestment of an additional $50,000in a money market account during 2022 and higher average interest rates for the year ended December 31, 2022 compared to 2021.

(amounts in thousands, except for par value)
As of December 31,
Current assets
Cash and cash equivalents$110,890$136,377
Restricted cash110110
Prepaid expenses4,0312,488
Research and development tax rebate receivable7431,072
Other current assets2,4231,193
Total current assets118,197141,240
Investment in equity securities4,700-
Other assets63522
Total Assets$123,532$141,262
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable$2,965$1,717
Accrued expenses1,059204
Payroll liabilities1,5251,184
Other current liabilities1921
Total current liabilities5,5683,126
Total Liabilities5,5683,126
Commitments and contingencies
Stockholders' equity
Series B convertible preferred stock - $0.001 par value; 10,000 shares authorized; 1 shares issued and outstanding as of December 31, 2022 and December 31, 2021--
Additional paid-in capital - Series B convertible preferred stock582582
Common stock - $0.18 par value; 175,000 shares authorized; 126,624 shares issued and outstanding as of December 31, 2022 and December 31, 202122,79222,792
Additional paid-in capital - common stock250,784243,996
Accumulated deficit(156,194)(129,234)
Total Stockholders' Equity117,964138,136
Total Liabilities and Stockholders' Equity$123,532$141,262
(amounts in thousands, except for per share amounts)
For the Year Ended
December 31,
Operating expenses
Research and development$15,083$9,210
General and administrative12,60811,311
Total operating expenses27,69120,521
Operating loss(27,691)(20,521)
Interest income8776
Other expense, net(146)(91)
Loss before income taxes(26,960)(20,606)
Income taxes--
Net loss(26,960)(20,606)
Loss per share of common stock - basic and diluted$(0.21)$(0.18)
Weighted average shares outstanding - basic and diluted126,624116,950


Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer. For more information, please visit

Kyle Guse
General Counsel and Chief Financial Officer

(Video) Get Rich with Atossa Therapeutics Stock ATOS | Atossa Therapeutics Stock Analysis & Earnings

Eric Van Zanten
VP, Investor and Public Relations

Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with any variation between interim and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of (Z)-endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa’s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in breast density or in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for (Z)-endoxifen, whether Atossa can complete acquisitions, and other risks detailed from time to time in Atossa’s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update (2)
Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update (3)

Atossa Therapeutics Announces Year-End 2022 Financial Results and Provides Corporate Update (4)


1. Atossa Therapeutics Stock : ATOS Stock Analysis News - Prediction, Earnings Report ($ATOS 8/13)
(Money Journey With Sonny)
2. Atossa Therapeutics Inc (ATOS) - Heavy Institutional buying and great quarter.
3. Atos Announces Major Restructure
4. ATOS to $100?! | HUGE Trial Data News Coming! | Atossa Therapeutics Stock Analysis
5. $KTRA Stock Kintara Therapeutics Could Triple By End of Year! Rare Disease and Orphan FDA Fastrack!
(Dan Sfera)
6. Atossa Therapeutics Stock : ATOS Stock Analysis - Prediction, Short Interest and Options Updates
(Money Journey With Sonny)


Top Articles
Latest Posts
Article information

Author: Patricia Veum II

Last Updated: 01/21/2023

Views: 5588

Rating: 4.3 / 5 (44 voted)

Reviews: 91% of readers found this page helpful

Author information

Name: Patricia Veum II

Birthday: 1994-12-16

Address: 2064 Little Summit, Goldieton, MS 97651-0862

Phone: +6873952696715

Job: Principal Officer

Hobby: Rafting, Cabaret, Candle making, Jigsaw puzzles, Inline skating, Magic, Graffiti

Introduction: My name is Patricia Veum II, I am a vast, combative, smiling, famous, inexpensive, zealous, sparkling person who loves writing and wants to share my knowledge and understanding with you.